Home The History of Synthetic Biology Designing Synthetic Biotics Pipeline Our People Leadership Board of Directors Founders and Advisors Investors + Media Company Overview News News Releases In the News Events & Presentations Events Presentations Publications Stock Information Stock Quote & Chart Analyst Coverage Corporate Governance Governance Highlights Management Team Board of Directors Committee Composition Board Diversity Matrix Financials Quarterly Results Investor Resources FAQs Contact IR Email Alerts RSS Feeds Synlogic Announces Closing of $21.0 Million Underwritten Public Offering Read more about Synlogic Announces Closing of $21.0 Million Underwritten Public Offering Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering Read more about Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism Read more about Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism Synlogic Announces Reverse Stock Split Read more about Synlogic Announces Reverse Stock Split Synlogic to Participate in Chardan’s Genetic Medicines Conference Read more about Synlogic to Participate in Chardan’s Genetic Medicines Conference Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100 Read more about Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100 Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update Read more about Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria Read more about Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria Synlogic Announces International Nonproprietary Name Selection for SYNB1934 Read more about Synlogic Announces International Nonproprietary Name Selection for SYNB1934 Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum Read more about Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum Pagination First page « First Previous page ‹ Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to Investor Resources Contact IR Investor FAQs RSS Feeds Investor Email Alerts Email
Synlogic Announces Closing of $21.0 Million Underwritten Public Offering Read more about Synlogic Announces Closing of $21.0 Million Underwritten Public Offering
Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering Read more about Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering
Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism Read more about Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism
Synlogic to Participate in Chardan’s Genetic Medicines Conference Read more about Synlogic to Participate in Chardan’s Genetic Medicines Conference
Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100 Read more about Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100
Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update Read more about Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update
Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria Read more about Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria
Synlogic Announces International Nonproprietary Name Selection for SYNB1934 Read more about Synlogic Announces International Nonproprietary Name Selection for SYNB1934
Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum Read more about Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum